血小板减少能否预测主动脉瓣置换术后短期死亡?
该回顾性单中心研究纳入216例主动脉瓣置换患者(TAVI 67例,sAVR 149例),采用倾向性评分重叠加权比较两组术后血小板及炎症指标变化。结果显示TAVI与sAVR术后血小板和炎症反应时间模式不同,但校正后这些生物标志物变化与90天死亡率无独立关联,仅EuroSCORE II仍独立相关。
要点
- TAVI与sAVR术后血小板及炎症指标时间模式存在显著交互作用(PLT p=0.001,NLR p<0.001,PLR p=0.002)。
- 术后第3天sAVR中度血小板减少更常见(33.5% vs 8.3%),TAVI正常血小板更常见(45.6% vs 8.2%)。
- 校正后仅EuroSCORE II独立预测90天死亡,血小板变化非独立预后标志。
核心结论
- TAVI与sAVR术后血小板和炎症反应时间模式不同,但校正后这些变化与90天死亡率无独立关联,EuroSCORE II仍独立相关。
研究设计与样本
- 回顾性单中心研究,纳入2015–2020年216例主动脉瓣置换患者,TAVI 67例、sAVR 149例;主要比较队列含TAVI 67例和sAVR 93例,采用倾向性评分重叠加权。
主要发现
- PLT、NLR、PLR的治療×时间交互作用显著(p分别为0.001、<0.001、0.002)。
- 术后第3天sAVR中度血小板减少比例高于TAVI(33.5% vs 8.3%),TAVI正常血小板比例更高(45.6% vs 8.2%;总体p<0.001)。
- 加权90天死亡率TAVI与sAVR无显著差异(12.6% vs 17.5%,p=0.487)。
- Firth回归中仅EuroSCORE II与90天死亡率独立相关。
关键数值与推荐
- 主要比较队列TAVI 67例、sAVR 93例;术后第3天中度血小板减少sAVR 33.5% vs TAVI 8.3%,正常血小板TAVI 45.6% vs sAVR 8.2%(总体p<0.001)。
- 加权90天死亡率TAVI 12.6% vs sAVR 17.5%(p=0.487)。
- PLT交互作用p=0.001,NLR交互作用p<0.001,PLR交互作用p=0.002。
临床怎么用
- 连续血常规变化应结合基线临床风险(如EuroSCORE II)解读,而非单独作为预后标志。
- sAVR术后更常见中度血小板减少,TAVI术后更常见正常血小板水平,监测时需考虑术式差异。
局限性
- 机械瓣患者保留在总队列但排除于主要TAVI-sAVR比较,可能影响外推性。
- 仅评估90天死亡率,未涉及长期结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Postprocedural thrombocytopenia is frequently observed after transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (sAVR), but its independent prognostic value remains unclear. We investigated whether platelet reduction after TAVI and sAVR independently predicts short-term mortality beyond baseline procedural risk. METHODS: This retrospective single-center study included 216 patients who underwent aortic valve replacement between 2015 and 2020. Sixty-seven patients underwent TAVI and 149 underwent sAVR. Mechanical valve recipients were retained in the overall cohort but excluded from the primary TAVI-sAVR comparison. Propensity score overlap weighting was used to reduce baseline differences between groups. Longitudinal changes in platelet count (PLT), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) were evaluated using generalized estimating equation models, and factors associated with 90-day mortality were assessed using Firth penalized logistic regression. RESULTS: The primary comparative cohort included 67 TAVI and 93 sAVR patients. After overlap weighting, adequate balance was achieved for all measured baseline covariates. Significant treatment × time interactions were observed for PLT (p = 0.001), NLR (p < 0.001), and PLR (p = 0.002). On postprocedural day 3, moderate thrombocytopenia was more frequent after sAVR than TAVI (33.5% vs. 8.3%), whereas normal platelet levels were more frequent after TAVI (45.6% vs. 8.2%; overall p < 0.001). Weighted 90-day mortality did not differ significantly between TAVI and sAVR (12.6% vs. 17.5%, p = 0.487). In Firth regression models, only EuroSCORE II remained independently associated with 90-day mortality. CONCLUSION: Postprocedural platelet and inflammatory responses showed different temporal patterns after TAVI and sAVR. However, these biomarker changes were not independently associated with 90-day mortality after adjustment, whereas EuroSCORE II remained independently associated with mortality. Serial hematological changes should therefore be interpreted together with baseline clinical risk rather than as isolated prognostic markers.
引用
- Taban, Güner, Alsancak, et al. Does thrombocytopenia predict short-term mortality after transcatheter and surgical aortic valve replacement? Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42958636. doi:10.1093/icvts/ivag295
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。